Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00151333 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)
A Phase 2 study of Alzheimers Disease, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 3
- Study locations
NCT00151333 is a Phase 2 study of Alzheimers Disease that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 16 participants, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT00151333, a Phase 2 study of Alzheimers Disease, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 3
- Study locations
Study Summary
To determine the safety and tolerability of multiple ascending fixed oral doses of SRA-333 in subjects with mild to moderate Alzheimer's disease.
Conditions Studied
Interventions
- DRUG SRA-333
Study Locations (3)
Florida
- - Fort Lauderdale
- - Miami
Arizona
- - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2005-02 |
| Est. Completion | 2005-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00151333
The ClinicalTrials.gov registry entry for NCT00151333 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (100% lower). The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which SRA-333 is the first listed.
NCT00151333 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00151333 about?
NCT00151333 is a clinical study titled "Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)". To determine the safety and tolerability of multiple ascending fixed oral doses of SRA-333 in subjects with mild to moderate Alzheimer's disease.
What is the current status of trial NCT00151333?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2005-02. Estimated completion is 2005-04.
What conditions does trial NCT00151333 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT00151333?
The interventions under investigation include: SRA-333 (DRUG).
Who is sponsoring clinical trial NCT00151333?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00151333 being conducted?
This trial has 3 study locations across Arizona, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.